RxDoctor Payments Data

Daniela Karanda, APRN

Family · Hebron, CTNPI 1558730630

Payments from drug & device makers

$700in general payments, 2019–2025

Across 28 payments — averaging $24.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$187
  • Novo Nordisk$171
  • Dynavax Technologies Corporation$92
  • AbbVie$69
  • Pfizer$56
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$42
  • plus $83 from 3 others

What the payments were for

  • Food & beverage$700100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$700 in reported general payments places this provider in the 65th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$25,654
Medicare patients
95
Services billed
282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$57,260
EliquisApixaban33$25,605
JanumetSitagliptin Phos/Metformin Hcl18$20,995
JanuviaSitagliptin Phosphate12$20,009
MounjaroTirzepatide13$16,902
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$16,814
Breo ElliptaFluticasone/Vilanterol24$14,762
XareltoRivaroxaban16$11,378
OxycontinOxycodone Hcl11$6,328
SynthroidLevothyroxine Sodium20$1,618
Levothyroxine Sodium166$1,529
Atorvastatin Calcium183$1,431
Metoprolol Succinate69$1,013
Lisinopril153$987
Pantoprazole Sodium77$943

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$171$57,26029 claims
PfizerEliquis$56$25,60533 claims
Lilly USA, LLCMounjaro$187$16,90213 claims
AbbVieSynthroid$69$1,61820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,596 family providers in Connecticut.

Other family in Hebron

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →